ArticleSchizophrenia research2015
Longitudinal regional brain volume loss in schizophrenia: Relationship to antipsychotic medication and change in social function.
Article in Schizophrenia research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic and Meta-analytic Review of Neural Correlates of Functional Outcome in Schizophrenia.Schizophrenia bulletin · 2017Pooled it
- Neural substrates of treatment-resistant schizophrenia and the response to clozapine: A structural MRI study in a clinical setting.PloS one · 2026Article
- Longitudinal Development of Neurocognitive Functioning and Gray Matter Volume in Youths With Recurrent Psychosis Spectrum Symptoms.Schizophrenia bulletin · 2025Article
- Associations Between Klotho Levels,Schizophrenia bulletin open · 2025Article
- A roadmap towards standardized neuroimaging approaches for human thalamic nuclei.Nature reviews. Neuroscience · 2024Review
- Neurostructural changes in schizophrenia and treatment-resistance: a narrative review.Psychoradiology · 2024Review
- Targeted Treatment of Schizophrenia Symptoms as They Manifest, or Continuous Treatment to Reduce the Risk of Psychosis Recurrence.Schizophrenia bulletin · 2024Article
- An fNIRS investigation of novel expressed emotion stimulations in schizophrenia.Scientific reports · 2023Article
- Antipsychotics and structural brain changes: could treatment adherence explain the discrepant findings?Therapeutic advances in psychopharmacology · 2023Review
- Hub-connected functional connectivity within social brain network weakens the association with real-life social network in schizophrenia patients.European archives of psychiatry and clinical neuroscience · 2022Article
- Exploring Links Between Psychosis and Frontotemporal Dementia Using Multimodal Machine Learning: Dementia Praecox Revisited.JAMA psychiatry · 2022Article
- An observational study of antipsychotic medication discontinuation in first-episode psychosis: clinical and functional outcomes.Social psychiatry and psychiatric epidemiology · 2022Observational
- Evaluation of functional MRI-based human brain parcellation: a review.Journal of neurophysiology · 2022Review
- Total Brain Volumetric Measures and Schizophrenia Risk: A Two-Sample Mendelian Randomization Study.Frontiers in genetics · 2022Article
- Increased subcortical region volume induced by electroconvulsive therapy in patients with schizophrenia.European archives of psychiatry and clinical neuroscience · 2021Article
- The progression of disorder-specific brain pattern expression in schizophrenia over 9 years.NPJ schizophrenia · 2021Article
- Peripheral immune markers and antipsychotic non-response in psychosis.Schizophrenia research · 2021Article
- Relational Memory in the Early Stage of Psychosis: A 2-Year Follow-up Study.Schizophrenia bulletin · 2021Article
- A Random Forest Model for Predicting Social Functional Improvement in Chinese Patients with Schizophrenia After 3 Months of Atypical Antipsychotic Monopharmacy: A Cohort Study.Neuropsychiatric disease and treatment · 2021Article
- Changes in Brain Structure, Function, and Network Properties in Patients With First-Episode Schizophrenia Treated With Antipsychotics.Frontiers in psychiatry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundProgressive brain volume loss in schizophrenia has been reported in previous studies but its cause and regional distribution remains unclear. We investigated progressive regional brain reductions in schizophrenia and correlations with potential mediators.
methodParticipants were drawn from the Northern Finland Birth Cohort 1966. A total of 33 schizophrenia individuals and 71 controls were MRI scanned at baseline (mean age=34.7, SD=0.77) and at follow-up (mean age=43.4, SD=0.44). Regional brain change differences and associations with clinical mediators were examined using FSL voxelwise SIENA.
resultsSchizophrenia cases exhibited greater progressive brain reductions than controls, mainly in the frontal and temporal lobes. The degree of periventricular brain volume reductions were predicted by antipsychotic medication exposure at the fourth ventricular edge and by the number of days in hospital between the scans (a proxy measure of relapse duration) at the thalamic ventricular border. Decline in social and occupational functioning was associated with right supramarginal gyrus reduction.
conclusionOur findings are consistent with the possibility that antipsychotic medication exposure and time spent in relapse partially explain progressive brain reductions in schizophrenia. However, residual confounding could also account for the findings and caution must be applied before drawing causal inferences from associations demonstrated in observational studies of modest size. Less progressive brain volume loss in schizophrenia may indicate better preserved social and occupational functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.